Which meds should be used with caution in HF due to potential negative inotropic effects?

• A. Calcium channel blockers, tricyclic antidepressants, carbamazepine, itraconazole, and class I antiarrhythmics
• B. ACE inhibitors and ARBs
• C. SGLT2 inhibitors
• D. Diuretics

Answer: (A)

The main idea is that certain medications can weaken the heart’s pumping strength, which is especially risky in heart failure. In systolic heart failure, anything that has a negative inotropic effect—reducing how forcefully the heart muscle contracts—can worsen symptoms or function.

Calcium channel blockers, particularly the non-dihydropyridine ones like verapamil and diltiazem, slow conduction and directly reduce contractility. In heart failure with reduced ejection fraction, this can lower cardiac output and worsen status, so these are used with caution or avoided.

Tricyclic antidepressants can impact cardiac conduction and myocyte contractility through anticholinergic effects and sodium channel blockade, potentially worsening heart failure symptoms and provoking arrhythmias. This is why caution is advised in HF patients.

Carbamazepine, a sodium channel blocker used for seizures and neuropathic pain, can also depress myocardial function and interact unfavorably with heart failure management, warranting cautious use.

Itraconazole has been reported to have negative inotropic effects and has been associated with heart failure in susceptible individuals, so it’s approached cautiously in HF.

Class I antiarrhythmics (sodium channel blockers used to treat arrhythmias) can decrease contractility and carry proarrhythmic risk in structural heart disease, making them safer options limited in HF unless benefits clearly outweigh risks.

In contrast, medications like ACE inhibitors and ARBs, SGLT2 inhibitors, and diuretics are either beneficial or neutral regarding heart muscle contractility and are central to HF management, not a cause for caution from negative inotropy.

So the meds you should use with caution in heart failure due to potential negative inotropic effects include the non-dihydropyridine calcium channel blockers, tricyclic antidepressants, carbamazepine, itraconazole, and class I antiarrhythmics.